 | Novo Nordisk steady amid Lilly Retatrutide risks |
December 12, 2025 at 11:14 am
|
 | No plane sailing for Novo Nordisk |
November 25, 2025 at 08:20 am
|
 | Novo Nordisk valuation hit by obesity fears |
November 25, 2025 at 04:42 am
|
| Novo Nordisk faces US drug price cuts but gains wider obesity coverage |
November 10, 2025 at 08:52 am
|
| Novo Nordisk faces earnings miss and guidance cut amid obesity drug Competition |
November 05, 2025 at 10:16 am
|
| NOVO NORDISK : Exhibiting aggression, Novo gatecrashes Pfizer-Metsera's party |
October 31, 2025 at 10:18 am
|
 | All hands on deck at Novo Nordisk! |
September 10, 2025 at 06:04 am
|
 | Novo Nordisk: Wegovy - beyond diabetes and obesity |
August 19, 2025 at 04:17 am
|
 | Novo Nordisk falters once again |
July 29, 2025 at 09:39 am
|
 | How did Novo Nordisk lose the US market? |
July 02, 2025 at 06:11 am
|
 | The Parvus fund enters Novo Nordisk's capital |
June 10, 2025 at 08:06 am
|
 | Wegovy on the rise amongst American teens; between effectiveness and reluctance |
June 04, 2025 at 05:01 am
|
 | Novo Nordisk CEO ousted as battle against obesity intensifies |
May 16, 2025 at 09:40 am
|
 | MarketScreener roundup: abysmal trade deficit and massive share buybacks in the US; Novo Nordisk's valuation on a diet |
May 07, 2025 at 06:06 am
|
 | Novo Nordisk is weak, but that's enough |
May 07, 2025 at 04:27 am
|
 | Novo Nordisk: Penalized by Eli Lilly's success |
April 22, 2025 at 08:06 am
|
 | Novo Nordisk under threat from first anti-obesity generics |
March 10, 2025 at 10:37 am
|
 | Cagrisema sends Novo Nordisk to the mat |
December 20, 2024 at 06:20 am
|
 | Novo Nordisk A/S: Volatility continues unabated |
November 07, 2024 at 12:28 pm
|
 | Novo Nordisk doesn't disappoint |
January 31, 2024 at 10:48 am
|
| Novo Nordisk A/S : "With obesity, we're dealing with a billion patients worldwide". |
August 25, 2023 at 09:40 am
|
 | Novo Nordisk AS : Global leader in diabetes treatments |
November 14, 2019 at 06:13 am
|
